In SURPASS 4 The risk of suffering from any major adverse cardiovascular event MACE-4 and MACE-3 (including myocardial infarction, stroke, hospitalization for angina, and all-cause death) with the highest dose of tirzepatide (15 mg per week) has been estimated at 050 (026095), which was intended to provide initial proof of the cardiovascular safety of tirzepatide [2, 5]
Safety research is mostly from adults
After 16 weeks, patients on Rozebalamin had experienced a 43% lower decline in ALSFRS-R scores, indicating a significant slowing in disease progression, compared with a placebo
Additionally, excluding patients with a diagnosis of any psychiatric diseases within one year before or one month after the index date may not be sufficient to avoid bias
If additional documentation is needed, it can be submitted at this stage. File an appeal If your insurance denies Ozempic coverage, your healthcare provider can file an appeal to advocate for its medical necessity
M.WoottenD.ChristopoulosA